Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | April 03, 2023 | April 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date April 03, 2023 · Filed April 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby CLAT | 125,493 |
Reported balance
After 2023-04-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-04-03 · Gift · Disposed 259 · Balance 125,493 |
| Common StockSEC Table I · non-derivative | Direct | 312,578 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 312,578 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,963 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,963 |
| Common StockSEC Table I · non-derivative | Indirectby Spouse as Trustee | 23,461 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 23,461 |
| Common StockSEC Table I · non-derivative | Indirectby trust for grandch | 3,609 |
Reported balance
Holding disclosure · report date 2023-04-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 3,609 F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust. |
Filing footnotes · ownership attribution and instrument terms
F1: By trusts for the benefit of nine grandchildren of the reporting person, each of which holds 401 shares of Company stock. The reporting person and/or the spouse of the reporting person is the trustee of each such trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2017 Filed Aug 18, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 2,900 | $470.15 | $1,363,435.00 |
DisclosureSEC source: 0001708138-17-000015 · edgardoc.xml · nonDerivative · entry 7 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,756 F3 · price: Represents volume-weighted average price of sales of 2,900 shares of Company stock on August 18, 2017 at prices ranging from $470.00 to $470.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 18, 2017 at each separate price. Read SEC document |
| August 17, 2017 Filed Aug 18, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,305 | $470.00 | $613,350.00 |
DisclosureSEC source: 0001708138-17-000015 · edgardoc.xml · nonDerivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 388,656 F2 · price: Represents volume-weighted average price of sales of 1,305 shares of Company stock on August 17, 2017 at prices ranging from $470.00 to $470.03. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 17, 2017 at each separate price. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 153,969 | $0.00 Strike: $21.92 | $0.00 |
DisclosureSEC source: 0001708138-17-000015 · edgardoc.xml · derivative · entry 12 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,969 Underlying: Common Stock · 153,969 shares Expires 2017-12-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 10,986 | $470.17 | $5,165,287.62 |
DisclosureSEC source: 0001708138-17-000015 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389,961 F1 · price: Represents volume-weighted average price of sales of 10,986 shares of Company stock on August 16, 2017 at prices ranging from $470.00 to $470.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 16, 2017 at each separate price. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 75,406 | $471.41 | $35,547,142.46 |
DisclosureSEC source: 0001708138-17-000015 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,947 Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 7,159 | $471.41 | $3,374,824.19 |
DisclosureSEC source: 0001708138-17-000015 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,353 Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 153,969 | $21.92 | $3,375,000.48 |
DisclosureSEC source: 0001708138-17-000015 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2017 Filed Aug 18, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 84,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-17-000015 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,543 Read SEC document |
| July 03, 2017 Filed Aug 18, 2017 21:00 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 422 | $0.00 | $0.00 |
DisclosureSEC source: 0001708138-17-000015 · edgardoc.xml · nonDerivative · entry 8 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 150,285 Read SEC document |
| May 25, 2017 Filed May 26, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 800 | $459.24 | $367,392.00 |
DisclosureSEC source: 0001237899-17-000017 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 83,652 F3 · price: Represents volume-weighted average price of sales of 800 shares of Company stock on May 25, 2017 at prices ranging from $459.01 to $459.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 25, 2017 at each separate price. Read SEC document |
| May 25, 2017 Filed May 26, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 4,985 | $458.35 | $2,284,874.75 |
DisclosureSEC source: 0001237899-17-000017 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 84,452 F2 · price: Represents volume-weighted average price of sales of 4,985 shares of Company stock on May 25, 2017 at prices ranging from $458.00 to $458.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 25, 2017 at each separate price. Read SEC document |
| May 25, 2017 Filed May 26, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3,510 | $457.58 | $1,606,105.80 |
DisclosureSEC source: 0001237899-17-000017 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by Spouse as Trustee Disclosed balance after: 89,437 F1 · price: Represents volume-weighted average price of sales of 3,510 shares of Company stock on May 25, 2017 at prices ranging from $457.05 to $457.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on May 25, 2017 at each separate price. Read SEC document |
| April 03, 2017 Filed May 26, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 547 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000017 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 150,707 Read SEC document |
| January 03, 2017 Filed May 26, 2017 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 571 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-17-000017 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 151,254 Read SEC document |
| December 16, 2016 Filed Dec 20, 2016 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 78,302 | $0.00 Strike: $381.92 | $0.00 |
DisclosureSEC source: 0001237899-16-000095 · edgardoc.xml · derivative · entry 6 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,302 Underlying: Common Stock · 78,302 shares Expires 2026-12-16 F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 22, 2016 Filed Dec 20, 2016 21:29 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 59,788 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000095 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 414,156 Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 76,895 | $0.00 Strike: $20.32 | $0.00 |
DisclosureSEC source: 0001237899-16-000082 · edgardoc.xml · derivative · entry 9 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 76,895 shares Expires 2016-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 37,388 | $355.52 | $13,292,181.76 |
DisclosureSEC source: 0001237899-16-000082 · edgardoc.xml · nonDerivative · entry 3 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 473,944 Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 4,394 | $355.52 | $1,562,154.88 |
DisclosureSEC source: 0001237899-16-000082 · edgardoc.xml · nonDerivative · entry 2 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,332 Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 76,895 | $20.32 | $1,562,506.40 |
DisclosureSEC source: 0001237899-16-000082 · edgardoc.xml · nonDerivative · entry 1 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 515,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 03, 2016 Filed Nov 9, 2016 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 531 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000082 · edgardoc.xml · nonDerivative · entry 5 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 151,825 Read SEC document |
| July 01, 2016 Filed Nov 9, 2016 21:10 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GiftCommon Stock | 608 | $0.00 | $0.00 |
DisclosureSEC source: 0001237899-16-000082 · edgardoc.xml · nonDerivative · entry 4 VAGELOS P ROY · CIK 0001013064 · Director · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · by CLAT Disclosed balance after: 152,356 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.